Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
Hinata N, Yonese J, Masui S, Nakai Y, Shirotake S, Tatsugami K, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Ochi K, Kaneko H, Uemura H. Hinata N, et al. Among authors: shirotake s. Int J Clin Oncol. 2020 Aug;25(8):1533-1542. doi: 10.1007/s10147-020-01692-z. Epub 2020 Jun 9. Int J Clin Oncol. 2020. PMID: 32519026 Free PMC article.
Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Shirotake S, Hayakawa N, Kosaka T, Miyajima A, Momma T, Nakagawa K, Hasegawa S, Nakajima Y, Oya M. Tanaka N, et al. Among authors: shirotake s. BJU Int. 2013 Jul;112(2):E28-34. doi: 10.1111/bju.12133. BJU Int. 2013. PMID: 23795795
Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Ide H, Miyazaki Y, Obata J, Hoshino K, Shirotake S, Akita H, Kosaka T, Miyajima A, Momma T, Nakagawa K, Hasegawa S, Nakajima Y, Jinzaki M, Oya M. Tanaka N, et al. Among authors: shirotake s. Ann Surg Oncol. 2014 Mar;21(3):1038-45. doi: 10.1245/s10434-013-3349-z. Epub 2013 Nov 12. Ann Surg Oncol. 2014. PMID: 24217788
Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Hagiwara M, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Hasegawa S, Nakajima Y, Oya M. Tanaka N, et al. Among authors: shirotake s. Ann Surg Oncol. 2014 Sep;21(9):3151-8. doi: 10.1245/s10434-014-3657-y. Epub 2014 Mar 29. Ann Surg Oncol. 2014. PMID: 24682698
A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Oyama M, Momma T, Nakajima Y, Jinzaki M, Oya M. Tanaka N, et al. Among authors: shirotake s. Ann Surg Oncol. 2014 Nov;21(12):4041-8. doi: 10.1245/s10434-014-3830-3. Epub 2014 Jun 10. Ann Surg Oncol. 2014. PMID: 24912614
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
Tanaka N, Mizuno R, Shirotake S, Ito K, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Tanaka N, et al. Among authors: shirotake s. Urol Oncol. 2016 Jul;34(7):293.e17-25. doi: 10.1016/j.urolonc.2016.02.023. Epub 2016 Apr 1. Urol Oncol. 2016. PMID: 27040380
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Tanaka N, et al. Among authors: shirotake s. Urol Oncol. 2017 Feb;35(2):39.e19-39.e28. doi: 10.1016/j.urolonc.2016.10.001. Epub 2016 Nov 4. Urol Oncol. 2017. PMID: 27825515
Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.
Ito K, Masunaga A, Tanaka N, Mizuno R, Shirotake S, Yasumizu Y, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Momma T, Masuda T, Nakagawa K, Oyama M, Asano T, Oya M. Ito K, et al. Among authors: shirotake s. Jpn J Clin Oncol. 2019 Jan 1;49(1):69-76. doi: 10.1093/jjco/hyy154. Jpn J Clin Oncol. 2019. PMID: 30407543
113 results